Advertisement

Drug-induced acne

      Abstract

      A variety of drugs may provoke acne, with drug-induced acne (DIA) often having some specific clinical and histopathologic features. DIA is characterized by a medical history of drug intake, sudden onset, and an unusual age of onset, with a monomorphous eruption of inflammatory papules or papulopustules. The location of the acne lesions is beyond the seborrheic zone. Corticosteroids, anabolic steroids, testosterone, halogens, isoniazid, lithium, and some new anticancer agents are drugs with undoubted causal relationship to acne. The diagnosis of DIA is made by a detailed history with a record of drug onset, dosage regimen and therapy duration, absence of additional triggering factors, and clinical relationship between the introduction of the drug and the onset of an acne-like eruption. In all cases, the withdrawal of the drug should be followed by lessening of the acne lesions.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Clinics in Dermatology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Lobo A.
        • Mathai R.
        • Jacob M.
        Pathogenesis of drug induced acneform eruptions.
        Indian J Dermatol Venereol Leprol. 1992; 58: 159-163
        • Plewig G.
        • Jansen T.
        Acneiform dermatoses.
        Dermatology. 1998; 196: 102-107
        • Tsankov N.
        • Kazandjieva J.
        Drug induced acne.
        in: Zouboulis C.H. Katsambas A. Kligman A.M. Acne and Rosacea—Pathogenesis and Treatment. Springer, Berlin2014: 251-257 (Chapter 33)
        • Hurwitz R.M.
        Steroid acne.
        J Am Acad Dermatol. 1989; 21: 1179-1181
        • Abraham A.
        • Roga G.
        Topical steroid-damaged skin.
        Indian J Dermatol. 2014; 59: 456-459
        • Shibata M.
        • Katsuyama M.
        • Onodera T.
        • et al.
        Glucocorticoids enhance toll-like receptor 2 expression in human keratinocytes stimulated with propionibacterium acnes or proinflammatory cytokines.
        J Invest Dermatol. 2009; 129: 375-382
        • Liu K.
        • Antaya R.
        Midchildhood acne associated with inhaled corticosteroids: report of two cases and review of the literature.
        Pediatr Dermatol. 2014; 31: 712-715
        • HJ Y.
        • Lee S.K.
        • Son S.J.
        • et al.
        Steroid acne vs. Pityrosporum folliculitis: the incidence of Pityrosporum ovale and the effect of antifungal drugs in steroid acne.
        Int J Dermatol. 1998; 37: 772-777
        • Mills Jr., O.H.
        • Leyden J.J.
        • Kligman A.M.
        Tretinoin treatment of steroid acne.
        Arch Dermatol. 1973; 108: 381-384
        • Walker S.
        • Parry E.
        Acne induced by ‘Sus’ and ‘Deca’.
        Clin Exp Dermatol. 2006; 31: 297-298
        • Melnik B.
        • Jansen T.
        • Grabbe S.
        Abuse of anabolic-androgenic steroids and bodybuilding acne: an underestimated health problem.
        J Dtsch Dermatol Ges. 2007; 5: 110-117
        • Scott III, M.J.
        • Scott A.M.
        Effects of anabolic-androgenic steroids on the pilosebaceous unit.
        Cutis. 1992; 50: 113-116
        • Braunstein G.D.
        Management of female sexual dysfunction in postmenopausal women by testosterone administration: safety issues and controversies.
        J Sex Med. 2007; 4: 859-866
        • Weimann E.
        • Böhles H.J.
        Acute acne fulminans et conglobata after the end of high-dose testosterone therapy for hereditary tall stature.
        Klin Padiatr. 1999; 211: 410-412
        • Traupe H.
        • von Muehlendahl K.
        • Braemswig J.
        • et al.
        Acne of the fulminans type following testosterone therapy in three excessively tall boys.
        Arch Dermatol. 1988; 124: 414-417
        • Slayden S.M.
        Risks of menopausal androgen supplementation.
        Semin Reprod Endocrinol. 1998; 16: 145-152
        • Raza S.
        • Baig M.
        • Ali J.
        • et al.
        To study hypoactive sexual desire disorder in a fragile X carrier female successfully treated with local testosterone application.
        Int J Impot Res. 2008; 20: 226-228
        • Tsankov N.
        • Kazandjieva J.
        • Drenovska K.
        Drugs in exacerbation and provocation of psoriasis.
        Clin Dermatol. 1998; 16: 334-352
        • Yeung C.K.
        • Chan H.H.
        Cutaneous adverse effects of lithium: epidemiology and management.
        Am J Clin Dermatol. 2004; 5: 3-8
        • Plewig G.
        New concepts of drug induced acne.
        JEADV. 1995; 5: 10
        • Scarfi F.
        • Arunachalam M.
        Lithium acne.
        Can Med Assoc J. 2013; 185: 1525
        • Aithal V.
        • Appaih P.
        Lithium induced hidradenitis suppurativa and acne conglobata.
        Indian J Dermatol Venereol Leprol. 2004; 70: 307-309
        • Sinha S.
        • Udupa S.
        • Bhandary R.
        • et al.
        Sertraline-induced acneiform eruption.
        J Neuropsychiatry Clin Neurosci. 2014; 26: e56-e57
        • Ricci F.
        • Paradisi A.
        • Guerriero C.
        • et al.
        Acneiform eruption induced by ethosuximide.
        EJD. 2014; 24: 98-99
        • Khanna S.
        • Chirinos R.
        • Venna S.
        Escitalopram oxalate (Lexapro)-induced acneiform eruption.
        J Am Acad Dermatol. 2012; 67: e261-e263
        • Kansal N.
        • Sharma M.
        Acneiform eruption and pruritus in a patient with quetiapine therapy.
        Skinmed. 2013; 11: 317-318
        • Sharma R.P.
        • Kothari A.K.
        • Sharma N.K.
        Acneform eruptions and antitubercular drugs.
        Indian J Dermatol Venereol Leprol. 1995; 61: 26-27
        • Purohit S.D.
        • Gupta P.R.
        • Sharma T.N.
        • et al.
        Acne during rifampicin therapy.
        Ind J Tub. 1983; 30: 110-111
        • Tsankov N.
        • Kamarashev J.
        Rifampin in dermatology.
        Int J Dermatol. 1993; 32: 401-406
        • Ito K.
        • Hoshino H.
        • Nakazono T.
        • et al.
        Adverse effect other than liver dysfunction in treatment of latent tuberculous infection by isoniazid.
        Kekkaku. 2007; 82: 1-9
        • Cohen L.K.
        • George W.
        • Smith R.
        Isoniazid induced acne and pellagra. Occurrence in slow inactivators of isoniazid.
        Arch Dermatol. 1974; 109: 377-381
        • Jyonouchi H.
        • Lien K.W.
        • Aguila H.
        • et al.
        SAPHO osteomyelitis and sarcoid dermatitis in a patient with DiGeorge syndrome.
        Eur J Pediatr. 2006; 165: 370-373
        • Danby F.W.
        Acne and iodine: Reply.
        JAAD. 2007; 56: 164-165
        • Passarini B.
        • Infusino S.
        • Kasapi E.
        Chloracne: still cause for concern.
        Dermatology (Basel). 2010; 221: 63-70
        • Caputo R.
        • Monti M.
        • Ermacora E.
        • et al.
        Cutaneous manifestations of tetrachlorodibenzo-p-dioxin in children and adolescents. Follow-up 10 years after the Seveso, Italy, accident.
        J Am Acad Dermatol. 1988; 19: 812-819
        • Gawkrodger D.
        • Harris G.
        • Bojar R.
        Chloracne in seven organic chemists exposed to novel polycyclic halogenated chemical compounds (triazoloquinoxalines).
        Br J Dermatol. 2009; 161: 939-943
        • Fabbrocini G.
        • Kaya G.
        • Caseiro Silverio P.
        • et al.
        Aryl hydrocarbon receptor activation in acne vulgaris skin: a case series from the region of Naples, Italy.
        Dermatology (Basel). 2015; 231: 334-338
        • Balta I.
        • Ozuguz P.
        Vitamin B12-induced acneiform eruption.
        Cutan Ocul Toxicol. 2014; 33: 94-95
        • Aalfs A.S.
        • Scholvinck L.H.
        • Horváth B.
        Acneiform eruption in a 5-year-old due to vitamin B12 supplementation.
        Eur J Dermatol. 2013; 23: 1-2
        • Sherertz E.F.
        Acneiform eruption due to “megadose” vitamins B6 and B12.
        Cutis. 1991; 48: 119-120
        • Jansen T.
        • Romiti R.
        • Kreuter A.
        • et al.
        Rosacea fulminans triggered by high-dose vitamins B6 and B12.
        J Eur Acad Dermatol Venereol. 2001; 15: 484-485
        • Dupre A.
        • Albarel N.
        • Bonafe J.L.
        • et al.
        Vitamin B-12 induced acnes.
        Cutis. 1979; 24: 210-211
        • Braun-Falco O.
        • Lincke H.
        The problem of vitamin B6/B12 acne. A contribution on acne medicamentosa.
        Munch Med Wochenschr. 1976; 118: 155-160
        • Galimont-Collen A.
        • Vos L.
        • Lavrijsen A.
        • et al.
        Classification and management of skin, hair, nail and mucosal side-effects of epidermal growth factor receptor (EGFR) inhibitors.
        Eur J Cancer. 2007; 43: 845-851
        • Pérez-Soler R.
        • Delord J.P.
        • Halpern A.
        • et al.
        HER1/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1/EGFR Inhibitor Rash Management Forum.
        Oncologist. 2005; 10: 345-356
        • Sibaud V.
        • Tournier E.
        • Roche H.
        • et al.
        Late epidermal growth factor receptor inhibitor-related papulopustular rash: a distinct clinical entity.
        Clin Exp Dermatol. 2016; 41: 34-37
        • Dessinioti C.
        • Antoniou C.
        • Katsambas A.
        Acneiform eruptions.
        Clin Dermatol. 2014; 32: 24-34
        • Piérard-Franchimont C.
        • Blaise G.
        • Paquet P.
        • et al.
        Paroxysmal iatrogenic acne and the epidermal growth factor receptor inhibitors.
        Rev Med Liege. 2007; 62: 11-14
        • Molinari E.
        • De Quatrebarbes J.
        • André T.
        • et al.
        Cetuximab-induced acne.
        Dermatology. 2005; 211: 330-333
        • Gracia-Cazaña T.
        • Pastushenko I.
        • Concellón M.
        • et al.
        A comedonal acneiform eruption following dovitinib therapy.
        Clin Exp Dermatol. 2014; 39: 842-843
        • Lacouture M.E.
        Mechanisms of cutaneous toxicities to EGFR inhibitors.
        Nat Rev Cancer. 2006; 6: 803-812
        • Vaccaro M.
        • Guarneri F.
        • Borgia F.
        • et al.
        Efficacy, tolerability and impact on quality of life of clindamycin phosphate and benzoyl peroxide for the treatment of cetuximab-associated acneiform eruption in patients with metastatic colorectal cancer.
        J Dermatolog Treat. 2016; 27: 148-152
        • Gutzmer R.
        • Werfel T.
        • Mao R.
        • et al.
        Successful treatment with oral isotretinoin of acneiform skin lesions associated with cetuximab therapy.
        Br J Dermatol. 2005; 153: 849-851
        • Shin J.
        • Park J.
        • Cho B.
        • et al.
        Treatment of epidermal growth factor receptor inhibitor-induced acneiform eruption with topical recombinant human epidermal growth factor.
        Dermatology (Basel). 2012; 225: 135-140
        • Labianca R.
        • La Verde N.
        • Garassino M.C.
        Development and clinical indications of cetuximab.
        Int J Biol Markers. 2007; 22: 40-46
        • Kim K.B.
        • Kefford R.
        • Pavlick A.C.
        • et al.
        Phase II study of the MEK1/MEK2 inhibitor trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor.
        J Clin Oncol. 2013; 31: 482-489
        • Anforth R.
        • Liu M.
        • Nguyen B.
        • et al.
        Acneiform eruptions: a common cutaneous toxicity of the MEK inhibitor trametinib.
        Australas J Dermatol. 2014; 55: 250-254
        • Uribe P.
        • Anforth R.
        • Kefford R.
        • et al.
        Acneiform eruption in a patient with metastatic melanoma after ceasing combination dabrafenib/trametinib therapy.
        Melanoma Res. 2014; 24: 501-503
        • Gavrilova M.
        • Martin J.
        • Martin-Gorgojo A.
        • et al.
        Follicular acneiform eruption induced by bevacizumab.
        Dermatol Online J. 2012; 18: 15
        • Steels E.
        • Peretz A.
        • Vereecken P.
        Infliximab-induced acne: a new case and review of published reports.
        J Dermatolog Treat. 2009; 20: 59-60
        • Fernández-Crehuet P.
        • Ruiz-Villaverde R.
        Acneiform eruption as a probable paradoxical reaction to adalimumab.
        Int J Dermatol. 2015; 54: e306-e308
        • Kashat M.
        • Caretti K.
        • Kado J.
        Etanercept-induced cystic acne.
        Cutis. 2014; 94: 31-32
        • Kara A.
        • Alatas E.
        • Dogan G.
        • et al.
        A first case report of diffuse acneiform eruption caused by capecitabine in a patient with small-cell neuroendocrine lung carcinoma.
        J Oncol Pharm Pract. 2016; 22: 717-719
        • Formicone F.
        • Fargnoli M.C.
        • Pisani F.
        • et al.
        Cutaneous manifestations in Italian kidney transplant recipients.
        Transplant Proc. 2005; 37: 2527-2528
        • Mackesy M.
        • Selhorst C.
        • Raza S.
        Immunosuppressant-induced acneiform eruption of the breast.
        Breast J. 2014; 20: 650-652
        • Özcan D.
        • Seçkin D.
        • Ada S.
        • et al.
        Mucocutaneous disorders in renal transplant recipients receiving sirolimus-based immunosuppressive therapy: a prospective, case-control study.
        Clin Transplant. 2013; 27: 742-748
        • Kovalyshyn I.
        • Bijal A.
        • Lacouture M.
        • et al.
        Cyclophosphamide-associated acneiform drug eruption in a patient with multiple myeloma.
        J Am Acad Dermatol. 2011; 65: 657-659